2019 (n = 518) | 2020 (n = 441) | (n2020–n2019)/n2019 (%) | p value | |||
---|---|---|---|---|---|---|
n | % | N | % | |||
Cancer type | ||||||
Prostate | 340 | 65.64 | 292 | 66.21 | 14.12 | 0.851 |
Renal | 121 | 23.36 | 101 | 22.90 | 16.53 | 0.867 |
Urothelial | 42 | 8.11 | 38 | 8.62 | 9.52 | 0.776 |
Testicular | 15 | 2.90 | 10 | 2.27 | 33.33 | 0.543 |
Stage | ||||||
1 | 7 | 1.35 | 2 | 0.45 | 71.43 | 0.161 |
2 | 11 | 2.12 | 6 | 1.36 | 45.45 | 0.368 |
3 | 36 | 6.95 | 9 | 2.04 | 75.00 | < 0.0001* |
4 | 463 | 89.38 | 423 | 95.92 | 8.64 | < 0.0001* |
Missing | 1 | 0.19 | 1 | 0.23 | 0.00 | 0.271 |
SACT | ||||||
Chemotherapy | 112 | 21.62 | 71 | 16.10 | 36.61 | 0.0278 |
Immunotherapy (IO) | 43 | 8.30 | 50 | 11.34 | − 16.28 | 0.110 |
Hormone | 244 | 47.10 | 236 | 53.51 | 3.28 | 0.0455 |
Biological/targeted | 102 | 19.69 | 67 | 15.19 | 34.31 | 0.0574 |
Combo (Chemo/hormone) | 9 | 1.74 | 2 | 0.45 | 77.78 | 0.0574 |
Combo (Chemo/IO) | 1 | 0.19 | 1 | 0.23 | 0.00 | 0.920 |
Combo (Chemo/target) | 0 | 0.00 | 1 | 0.23 | N.A | 0.271 |
Combo (IO/Hormone) | 1 | 0.19 | 0 | 0.00 | 100.00 | 0.368 |
Combo (IO/target) | 5 | 0.97 | 13 | 2.95 | − 160.00 | 0.0214 |
Combo (Chemo/IO/hormone) | 1 | 0.19 | 0 | 0.00 | 100.00 | 0.368 |
Treatment paradigm | ||||||
Neoadjuvant | 11 | 2.12 | 6 | 1.36 | 45.45 | 0.368 |
Adjuvant | 17 | 3.28 | 6 | 1.36 | 64.71 | 0.0574 |
Radical | 18 | 3.47 | 1 | 0.23 | 94.44 | 0.00194* |
Palliative | 470 | 90.73 | 419 | 95.01 | 10.85 | 0.0124 |
Curative | 2 | 0.39 | 9 | 2.04 | − 350.00 | 0.0164 |
Line of palliative treatment (2019, n = 470; 2020, n = 419) | ||||||
1 | 94 | 20.00 | 117 | 27.92 | − 24.47 | 0.00194* |
2 | 248 | 52.77 | 257 | 61.34 | − 3.63 | 0.00137* |
3 | 87 | 18.51 | 30 | 7.16 | 65.52 | < 0.0001* |
4 | 26 | 5.53 | 10 | 2.39 | 61.54 | 0.0278 |
5 | 11 | 2.34 | 3 | 0.72 | 72.73 | 0.0574 |
6 | 2 | 0.43 | 2 | 0.48 | 0.00 | 0.841 |
7 | 1 | 0.21 | 0 | 0.00 | 100.00 | 0.368 |
Missing | 1 | 0.21 | 0 | 0.00 | 100.00 | 0.368 |
Trial treatment | ||||||
Yes | 64 | 12.36 | 52 | 11.79 | 18.75 | 0.790 |
SACT initiated during study period | ||||||
Yes | 118 | 22.78 | 102 | 23.13 | 13.56 | 0.898 |